DECENT is an Open-Source decentralized content distribution platform that utilizes Blockchain to ensure trust and security for content creators and enterprises. After the raising over $4.2 million worth of Bitcoins from their Initial Coin Offering, the startup expanded to China and closed additional partnerships.
Xigen, a SwissCompany developing therapeutic peptides for the treatment of inflammatory diseases, announced the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology.
Under the terms of the collaboration agreement, Anokion received a $45 million upfront payment and is eligible to receive a future payment of an additional $10 million based on certain preclinical development achievements. As part of the strategic collaboration agreement, Celgene obtained an equity interest in Anokion and the exclusive right to acquire Anokion at pre-specified option exercise points.
La 4ème édition du Salon des Technologies et de l’Innovation de Lausanne se tiendra le 2 mars prochain au SwissTech Convention Center de l’EPFL. Comme nous l’a expliqué la Présidente du STIL 2017, Victoria Letertre, le salon s’est fixé cette année un but ambitieux: faire découvrir les technologies des différentes entreprises et laboratoires présents de manière interactive pour les visiteurs.
PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, announced today that they have signed a collaboration agreement for the development of PIQUR’s lead compound PQR309 in dermato-oncology.
Early genomic testing can help identify an increased risk of particular types of cancer due to gene variants passed on from parent to child. Sophia Genetics Hereditary Cancer Solution helps quickly screen the 27 most relevant genes associated with hereditary cancer. It is the first solution of its kind which is CE-IVD marked.